Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Revenue of Stoke Therapeutics, Inc. (STOK)
Revenue in 2023 (TTM): $8.78 M
According to Stoke Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $8.78 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Stoke Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $8.78 M | $4.05 M | $-110,044,000 | $-104,699,000 | $-104,699,000 |
| 2022 | $12.41 M | $8.87 M | $-104,356,000 | $-101,067,000 | $-93,110,000 |
| 2021 | $ | $-2,230,000 | $-86,065,000 | $-85,805,000 | $-84,711,000 |
| 2020 | $ | $-1,926,000 | $-53,044,000 | $-52,243,000 | $-50,611,000 |
| 2019 | $ | $-450,000 | $-35,678,000 | $-32,325,000 | $-28,524,000 |
| 2018 | $ | $-214,000 | $-12,567,000 | $-12,521,000 | $-12,521,000 |
| 2017 | $ | $-113,000 | $-5,441,000 | $-5,558,000 | $-5,558,000 |